Cell Dec 10, 2025 Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy
FierceBiotech Dec 10, 2025 Chinese biotech led by AstraZeneca veteran reels in $108M for KRAS phase 3 plans
FierceBiotech Dec 10, 2025 Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial
Illumina Dec 10, 2025 Stifel reiterates Buy rating on Illumina stock, cites multiple growth levers - Investing.com UK
PLoS Biology Dec 10, 2025 Adaptations of the axon initial segment in fast-spiking interneurons of the human neocortex support low action potential thresholds
Endpoints News Dec 10, 2025 #SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%
Roche Media Dec 10, 2025 Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial - Fierce Biotech
PharmaVoice Dec 10, 2025 Another genetic testing company? Why a different approach could boost drug predictions and R&D.